Phaseline

Targets › FKRP

FKRP (Ribitol 5-phosphate transferase FKRP): drug programs, companies and trials

3 programs from 3 companies in 5 trials: 2 Phase 1, 2 Phase 3, 1 Phase 2; Neurology; next expected readout Nov 2026.

Catalyzes the transfer of a ribitol 5-phosphate from CDP-L-ribitol to the ribitol 5-phosphate previously attached by FKTN/fukutin to the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1). This constitutes the second step in the formation of the ribose 5-phosphate tandem repeat which…. (UniProt, Q9H9S5)

Open in Phaseline: the race on FKRP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ML Bio SolutionsBBP-418
substrate supplementation to enhance glycosylation of muscle α-dystroglycan
FKRPPhase 3Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I); LGMD2INov 2026
AskBioAB-1003
Gene therapy delivering functional FKRP gene
FKRPPhase 1Limb Girdle Muscular DystrophyDec 2028
Atamyo TherapeuticsATA-100
AAV9 gene therapy delivering FKRP gene
FKRPPhase 1LGMDR9Sep 2029

Conditions

Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) (2) Limb Girdle Muscular Dystrophy (1) LGMD2I (1) LGMDR9 (1)

Modalities

other (2), small molecule (1)

Companies

AskBio (1) ML Bio Solutions (1) Atamyo Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.